Lowest Price Guaranteed
Pages
237
Last Updated
September 2026
View Count
5556
1. PREFACE
1.1. Introduction
1.2. Market Key Insights
1.3. Market Segmentation
1.4. Market Share Insights
1.5. Key Questions Answered
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Chapter Overview
5.2. Executive Summary: Targeted Alpha Therapy Market Landscape
5.3. Executive Summary: Targeted Alpha Therapy Market Trends
5.4. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Targeted Alpha Therapy
6.2.1. Mechanism of Action of Targeted Alpha Therapy
6.2.2. Key Components of Targeted Alpha Therapy
6.2.2.1. Alpha-Emitting Radionuclides
6.2.2.2. Targeting Vectors
6.2.2.3. Molecular Targets and Tumor Biology
6.3. Targeted Alpha Therapy Development and Manufacturing Process
6.4. Advantages of Targeted Alpha Therapy
6.5. Challenges Associated with Targeted Alpha Therapy
6.6. Future Perspectives
7. TARGETED ALPHA THERAPY MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Targeted Alpha Therapy Market: Overall Market Landscape
7.3. Analysis by Stage of Development
7.4. Analysis by Type of Radionuclide
7.5. Analysis by Targeting Vector
7.6. Analysis by Molecular Target
7.7. Analysis by Therapeutic Area
7.8. Analysis by Geography
7.9. Targeted Alpha Therapy Market: Developer Landscape
7.9.1. Analysis by Location of Headquarters
7.9.2. Analysis by Year of Establishment
7.9.3. Analysis by Company Size
7.9.4. Most Active Players: Analysis by Number of Targeted Alpha Therapy Programs
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Actinium Pharmaceuticals
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Targeted Alpha Therapy Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AdvanCell
8.3.1. Company Overview
8.3.2. Targeted Alpha Therapy Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. Alpha-9 Oncology
8.4.1. Company Overview
8.4.2. Targeted Alpha Therapy Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Bayer
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Targeted Alpha Therapy Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. Blue Earth Therapeutics (part of the Bracco family)
8.6.1. Company Overview
8.6.2. Targeted Alpha Therapy Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Bristol Myers Squibb (including RayzeBio, its wholly owned subsidiary)
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Targeted Alpha Therapy Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Novartis
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Targeted Alpha Therapy Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. Orano Med (Orano Group subsidiary)
8.9.1. Company Overview
8.9.2. Targeted Alpha Therapy Portfolio
8.9.3. Recent Developments and Future Outlook
8.10. Perspective Therapeutics
8.10.1. Company Overview
8.10.2. Financial Information
8.10.3. Targeted Alpha Therapy Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. RadioMedix
8.11.1. Company Overview
8.11.2. Targeted Alpha Therapy Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Ratio Therapeutics
8.12.1. Company Overview
8.12.2. Targeted Alpha Therapy Portfolio
8.12.3. Recent Developments and Future Outlook
8.13. Sanofi
8.13.1. Company Overview
8.13.2. Financial Information
8.13.3. Targeted Alpha Therapy Portfolio
8.13.4. Recent Developments and Future Outlook
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Alpha Therapy: Clinical Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Status
9.3.3. Analysis by Trial Phase
9.3.4. Analysis by Trial Registration Year and Trial Status
9.3.5. Analysis by Trial Registration Year and Trial Phase
9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis by Study Design
9.3.8. Analysis by Type of Sponsor / Collaborator
9.3.9. Most Active Players: Analysis by Number of Registered Trials
9.3.10. Analysis of Trials by Geography
9.3.11. Analysis of Enrolled Patient Population by Geography
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Targeted Alpha Therapy Market: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Type of Partner
10.3.6. Analysis by Therapeutic Area
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Regional Analysis
10.3.8.1. Intracontinental and Intercontinental Agreements
10.3.8.2. Local and International Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Targeted Alpha Therapy Market: Funding and Investment Analysis
11.3.1. Analysis by Year of Funding
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested
11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis of Amount Invested by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players
11.3.5.1. Analysis by Number of Funding Instances
11.3.5.2. Analysis by Amount Raised
12. LIKELY PARTNER ANALYSIS
12.1. Chapter Overview
12.2. Assumptions and Key Parameters
12.3. Scope and Methodology
12.4. Potential Strategic Partners in North America
12.4.1. Most Likely Partners
12.4.2. Likely Partners
12.4.3. Less Likely Partners
12.5. Potential Strategic Partners Based in Europe
12.5.1. Most Likely Partners
12.5.2. Likely Partners
12.5.3. Less Likely Partners
12.6. Potential Strategic Partners Based in Asia-Pacific
12.6.1. Most Likely Partners
12.6.2. Likely Partners
12.6.3. Less Likely Partners
13. MARKET IMPACT ANALYSIS
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Challenges
13.5. Market Opportunities
13.6. Conclusion
14. GLOBAL TARGETED ALPHA THERAPY MARKET
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Targeted Alpha Therapy Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.4. Scenario Analysis
14.5. Key Market Segmentations
15. TARGETED ALPHA THERAPY MARKET, BY TYPE OF RADIONUCLIDE
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Targeted Alpha Therapy Market: Distribution by Type of Radionuclide
15.4. Targeted Alpha Therapy Market for Actinium-225 (Ac-225): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.5. Targeted Alpha Therapy Market for Radium-223 (Ra-223): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.6. Targeted Alpha Therapy Market for Lead-212 (Pb-212): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.7. Targeted Alpha Therapy Market for Other Alpha-Emitting Radionuclides: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.8. Data Triangulation and Validation
16. TARGETED ALPHA THERAPY MARKET, BY TARGETING VECTOR
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Targeted Alpha Therapy Market: Distribution by Targeting Vector
16.4. Targeted Alpha Therapy Market for Small-Molecule Ligands: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.5. Targeted Alpha Therapy Market for Peptides: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.6. Targeted Alpha Therapy Market for Antibodies / Antibody-Derived Vectors: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.7. Targeted Alpha Therapy Market for No Exogenous Vector / Physiologic Targeting: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.8. Targeted Alpha Therapy Market for Other Targeting Vectors: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.9. Data Triangulation and Validation
17. TARGETED ALPHA THERAPY MARKET, BY THERAPEUTIC AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Targeted Alpha Therapy Market: Distribution by Therapeutic Area
17.4. Targeted Alpha Therapy Market for Prostate Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.5. Targeted Alpha Therapy Market for Neuroendocrine Tumors: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.6. Targeted Alpha Therapy Market for Hematological Malignancies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.7. Targeted Alpha Therapy Market for Other Solid Tumors: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.8. Data Triangulation and Validation
18. TARGETED ALPHA THERAPY MARKET, BY END USER
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Targeted Alpha Therapy Market: Distribution by End User
18.4. Targeted Alpha Therapy Market for Hospitals & Academic Medical Centers: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.5. Targeted Alpha Therapy Market for Specialty Cancer & Nuclear Medicine Centers: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.6. Targeted Alpha Therapy Market for Other Authorized Treatment Facilities: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.7. Data Triangulation and Validation
19. TARGETED ALPHA THERAPY MARKET, BY GEOGRAPHY
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Targeted Alpha Therapy Market: Distribution by Geography
19.4. Targeted Alpha Therapy Market for North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.5. Targeted Alpha Therapy Market for Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.6. Targeted Alpha Therapy Market for Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.7. Targeted Alpha Therapy Market for Rest of World: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.8. Penetration Growth (P-G) Matrix
19.9. Data Triangulation and Validation
20. CONCLUDING INSIGHTS
20.1. Chapter Overview
20.2. Concluding Insights: Targeted Alpha Therapy Market Landscape
20.3. Concluding Insights: Targeted Alpha Therapy Market Trends
20.4. Concluding Insights: Market Forecast and Opportunity Analysis
21. INSIGHTS FROM PRIMARY RESEARCH
21.1. Chapter Overview
21.2. Company A
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Chief Executive Officer, Large Company, Germany
21.3. Company B
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Chief Executive Officer, Mid-sized Company, US
21.4. Company C
21.4.1. Company Snapshot
21.4.2. Interview Transcript: Chief Executive Officer, Small Company, Australia
21.5. Company D
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Chief Executive Officer, Small Company, Canada
21.6. Company E
21.6.1. Company Snapshot
21.6.2. Interview Transcript: President, Mid-sized Company, US
21.7. Company F
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Chair, Department of Radiology, Large Organization, US
21.8. Company G
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Vice President, Clinical Development, Large Organization, US
21.9. Company H
21.9.1. Company Snapshot
21.9.2. Interview Transcript: Director and Medical Director, Large Organization, US
21.10. Company I
21.10.1. Company Snapshot
21.10.2. Interview Transcript: Radiation Oncologist and Co-director, Very Large Organization, US
21.11. Company J
21.11.1. Company Snapshot
21.11.2. Interview Transcript: Doctor of Medicine, Very Large Organization, US
22. APPENDIX I: TABULATED DATA
23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS